Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma.

Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M, Debus J, Eble MJ, Sökler M, Ho A, Rank A, Ganser A, Trümper L, Bokemeyer C, Kirchner H, Schubert J, Král Z, Fuchs M, et al. N Engl J Med. 2010 Aug 12,363(7):640-52. doi: 10.1056/NEJMoa1000067.

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

Ludwig H, Adam Z, Hajek R, Greil R, TГіthovГЎ E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N. J Clin Oncol. 2010 Oct 20,28(30):4635-41. doi: 10.1200/JCO.2010.28.1238. Epub 2010 Sep 7.

Modulation of plasma complement by the initial dose of epirubicin/docetaxel therapy in breast cancer and its predictive value.

Michlmayr A, Bachleitner-Hofmann T, Baumann S, Marchetti-Deschmann M, Rech-Weichselbraun I, Burghuber C, Pluschnig U, Bartsch R, Graf A, Greil R, Allmaier G, Steger G, Gnant M, Bergmann M, Oehler R. Br J Cancer. 2010 Oct 12,103(8):1201-8. doi: 10.1038/sj.bjc.6605909. Epub 2010 Sep 28.

Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.

Early Breast Cancer Trialists‘ Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. J Natl Cancer Inst Monogr. 2010,2010(41):162-77. doi: 10.1093/jncimonographs/lgq039.

Neue Therapie in Sicht.

Merkel O, Kenner L, Greil R SpringerMedizin. 22.09.2010

Deletion of Puma and p21(Waf1) In Mice Deactivates p53-Induced Cell Death and Cell Cycle Arrest, but Protects Mice From Irradiation-Induced Lymphomagenesis by a Mechanism Involving Hemopoietic Stem Cell Quiescence

Hofbauer, JP, Holler, C, Denk, U, Asslaber, D, Fastner, G, Labi, V, Villunger, A, Greil, R, Egle, A BLOOD. 2010, 116(21): 45-46.

Final Analysis of Induction Treatment with Fludarabine, Cyclophosphamide Plus Rituximab (FCR) Followed by Fludarabine Plus Rituximab (FR) and Remission Maintenance Therapy with Rituximab In Previously Untreated B-Chronic Lymphocytic Leukemia (B-CLL): The Chairos AGMT CLL4/Roche ML18434 Study

Egle, A, Weiss, L, Melchardt, T, Gunsilius, E, Petzer, AL, Fridrik, M, Lang, A, Krieger, O, Thaler, J, Greil, R BLOOD. 2010, 116(21): 593-594.

Enzastaurin kills human CLL cells regardless of clinical risk profile, but fails to prolong life in a murine CLL model

Kocher, T, Pinon, HJ, Holler, C, Denk, U, Greil, R, Egle, A ONKOLOGIE. 2010, 33: 40-40.

microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.

Asslaber D, Piñón JD, Seyfried I, Desch P, Stöcher M, Tinhofer I, Egle A, Merkel O, Greil R. Blood. 2010 May 27,115(21):4191-7. doi: 10.1182/blood-2009-07-234823. Epub 2010 Jan 20.

Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia.

Merkel O, Asslaber D, PiГ±Гіn JD, Egle A, Greil R. Cell Cycle. 2010 Jul 15,9(14):2764-8. Epub 2010 Jul 3.